Gilead Sciences, Inc.

GILD

US3755581036

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

2023-12-11 - American Society of Hematology Meeting - Abstract Number : 1023

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

79.02USD

Average target price

90.39USD

Spread / Average Target

+14.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-6.72%	98 462 M $
ELI LILLY AND COMPANY	+59.64%	538 B $
NOVO NORDISK A/S	+42.69%	430 B $
JOHNSON & JOHNSON	-12.22%	372 B $
ABBVIE INC.	-6.42%	264 B $
MERCK & CO., INC.	-5.93%	263 B $
ROCHE HOLDING AG	-12.46%	232 B $
NOVARTIS AG	+2.38%	198 B $
PFIZER, INC.	-44.11%	163 B $
AMGEN INC.	+3.62%	144 B $

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 03:59:59 2023-12-11 pm EST			5-day change	1st Jan Change
80.08 ^USD	+1.34%		+2.22%	-6.72%

Dec. 06	Transgene: new CFO, share price rises	CF
Dec. 04	IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer	MT

Transgene: new CFO, share price rises	Dec. 06	CF
IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer	Dec. 04	MT
Ideaya Biosciences, Inc. Announces Clinical Study Collaboration with Gilead Sciences, Inc. to Evaluate Trodelvy and Ide397 Combination in Mtap-Deletion Bladder Cancer	Dec. 04	CI
Wall Street: ideal end to the session, perfect November	Nov. 30	CF
Amazon: 'Black Friday' and 're:Invent' support the stock	Nov. 29	CF
Transcript : Gilead Sciences, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 09:00 AM	Nov. 29	CI
Novartis' Kymriah, Other CAR-T Cancer Therapies Under US Investigation Over Alleged Safety Issues	Nov. 29	MT
US FDA investigating safety risk of CAR-T cancer therapies	Nov. 28	RE
Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup	Nov. 28	DJ
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells	Nov. 28	DJ
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs	Nov. 28	DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies	Nov. 28	MT
Transcript : Gilead Sciences, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 01:20 PM	Nov. 28	CI
US FDA investigating safety risk of CAR-T therapies	Nov. 28	RE
HOOKIPA Pharma's HIV Vaccine Candidate HB-500 Receives FDA Clearance for Investigational New-Drug Application	Nov. 20	MT
China Excludes Fosun Kite's Yescarta from Medical Insurance Program	Nov. 19	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	Nov. 15	MT
Sector Update: Health Care	Nov. 15	MT
Arcellx Shares Rise Premarket on Expanded Gilead Collaboration	Nov. 15	DJ
Arcellx Expands Partnership With Gilead Unit Kite	Nov. 15	MT
Gilead Invests Further in Arcellx, Extends Collaboration	Nov. 15	DJ
Transcript : Gilead Sciences, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-15-2023 09:00 AM	Nov. 15	CI
Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.	Nov. 14	CI
RBC Trims Price Target on Gilead Sciences to $77 From $78, Keeps Sector Perform Rating	Nov. 14	MT
UBS Adjusts Price Target on Gilead Sciences to $81 From $85, Maintains Neutral Rating	Nov. 13	MT